Drug profile · INN
naltrexone
ARX-NALTREXONE
naltrexone (ARX-NALTREXONE) is a opioid receptors; mu/kappa/delta antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — naltrexone
- US status
- approved
- Class
- Alimentary tract and metabolism (A08)
- Route
- INTRAMUSCULAR
- Patents
- 1
- Programs
- 38
- Data quality
- 0.89
Quick answer
naltrexone (ARX-NALTREXONE) is a opioid receptors; mu/kappa/delta antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Opioid receptors; mu/kappa/delta antagonist
Primary target: Opioid receptors; mu/kappa/delta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is naltrexone?
naltrexone (ARX-NALTREXONE) is a opioid receptors; mu/kappa/delta antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for naltrexone?
ARX-NALTREXONE is a marketed brand name for naltrexone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of naltrexone?
naltrexone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.